Currently, three new variants of the virus (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) are creating concern. They include:
A variant identified in the U.K. This COVID-19 variant (B.1.1.7) has 23 mutations. Several of these mutations are in the spikelike S protein that the virus uses to attach itself to the surface of human cells. Early research suggests that this variant spreads more easily and rapidly among people. The variant has been detected in many countries, including the U.S. There is no evidence that this variant has an impact of the effectiveness of COVID-19 vaccines.
A variant identified in South Africa. This variant (B.1.351) has multiple mutations in the S protein. Early research suggests that this variant is associated with higher amounts of virus in the body (viral load), which might make it easier for the variant to spread among people. The variant has been detected in a few other countries. Some evidence suggests that this variant might be less vulnerable to antibodies that can neutralize COVID-19.
A variant identified in Brazil. This variant (P.1) has 17 mutations, including 3 in the S protein. Some evidence suggests that this variant might spread more easily among people and be less vulnerable to antibodies generated by a previous COVID-19 infection or a COVID-19 vaccine.
There is no evidence that these COVID-19 variants cause more-severe illness with COVID-19 or an increased risk of death due to COVID-19.
In addition, new research that still needs to be finalized suggests that the Pfizer-BioNTech COVID-19 vaccine can protect against one of the mutations found in the variants identified in the U.K. and South Africa.
Further research is needed. In the meantime, keep following precautions for avoiding infection with the COVID-19 virus.
Follow the latest news on the coronavirus (COVID-19) outbreak
©2021 Mayo Clinic News Network
Distributed by Tribune Content Agency, LLC
What’s the concern with COVID-19 variants? (2021, January 25)
retrieved 25 January 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022